Inotiv, Inc. (NOTV) 股票分析

公司概述

Inotiv, Inc. (NOTV) operates within the healthcare sector, specifically focusing on diagnostics and research, by providing nonclinical and analytical drug discovery and development services to pharmaceutical and medical device industries across the United States, the Netherlands, and internationally. The company's business model is executed through two primary segments: Discovery and Safety Assessment (DSA) and Research Model, serving clients requiring rigorous preclinical testing and analytical support. In terms of scale, the company maintains a market capitalization of $9.18M, generates annual revenue of $514.03M, and employs a workforce of 1,945 individuals. The disparity between the relatively low market capitalization of $9.18M and the substantial annual revenue of $514.03M indicates that the market is currently pricing the company's equity significantly below its operational revenue base, suggesting a potential disconnect between current equity valuation and the scale of its revenue-generating activities.

财务健康

Inotiv, Inc. reported a total revenue of $514.03M for the trailing twelve months, while simultaneously posting a net income loss of $-69,373,000 and an EBITDA of $17.68M. The significant gap between the positive EBITDA of $17.68M and the negative net income of $-69,373,000 reveals a heavy cost structure driven by substantial non-operating expenses or interest costs that erode bottom-line profitability despite underlying operational earnings. The company's free cash flow stands at $-3,620,125, indicating that current cash generation is insufficient to cover capital expenditures and operational outflows, which constrains immediate financial flexibility for independent expansion without external financing. Analyzing the margin structure, the gross margin is 23.5%, while the operating margin is -13.4% and the profit margin is -13.5%, showing that while the company retains nearly a quarter of revenue as gross profit, overhead and other expenses exceed operating income by more than 13 percentage points. The balance sheet presents a highly leveraged profile with total debt of $475.97M against cash reserves of $12.73M, resulting in a debt-to-equity ratio of 436.57 which signifies aggressive leverage relative to shareholder equity. Short-term liquidity is constrained by a current ratio of 0.30, meaning current assets cover only 30% of current liabilities, highlighting a potential risk in meeting immediate obligations. Furthermore, the Return on Equity is -49.8% and the Return on Assets is -3.1%, metrics that collectively indicate that management's current strategy is reducing shareholder value and utilizing assets inefficiently to generate positive returns.

估值评估

The valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is -5.34, implying that the market expects earnings to remain negative or that the current earnings trajectory does not support a traditional multiple-based valuation. The price-to-book ratio is 0.08, indicating that the company's market capitalization is less than 10% of its book value, which suggests the market is pricing the equity well below the net asset value or that the book value includes significant intangible assets or goodwill not reflected in the low market price. Alternative valuation measures such as the price-to-sales ratio of 0.02 and an EV/EBITDA of 26.72 suggest that the stock is trading at a fraction of its sales revenue but carries a high enterprise value relative to its earnings power. In terms of price volatility, the 52-week high is $3.32 and the 52-week low is $0.24; without a specific current price provided in the source data, the position relative to this range cannot be calculated, but the historical range demonstrates a wide trading band. The beta value of 4.08 indicates that the stock's price volatility is approximately four times that of the broader market, signifying extreme sensitivity to market fluctuations and higher systematic risk for investors compared to lower beta assets.

Growth & Income

Revenue growth year-over-year is recorded at 0.8%, while earnings growth is N/A due to the company's negative net income position. The stagnation in revenue growth combined with the absence of earnings growth implies that the company is not expanding its top line at a pace that compensates for its heavy expense burden or that profitability has not yet been achieved to drive earnings expansion. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, effectively reinvesting all available resources or retaining capital to fund operations given the negative free cash flow context. Consequently, the overall growth and income profile is characterized by minimal revenue expansion and no income generation for shareholders, with the company relying on external capital markets or internal cash reserves to sustain its operations amidst significant debt obligations.